
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11069255/publications.pdf Version: 2024-02-01



STEEAN CLÂI/CK

#	Article	IF	CITATIONS
1	Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. Clinical Breast Cancer, 2021, 21, e575-e583.	2.4	7
2	Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor–positive metastatic breast cancer. Future Oncology, 2020, 16, 2661-2672.	2.4	6
3	Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer. Journal of Carcinogenesis, 2019, 18, 5.	2.5	4
4	Immunotherapy in breast cancer. Journal of Carcinogenesis, 2019, 18, 2.	2.5	56
5	Comparative effectiveness of early-line nab -paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis. Cancer Management and Research, 2018, Volume 10, 249-256.	1.9	21
6	Post-surgical depressive symptoms and long-term survival in non-metastatic breast cancer patients at 11-year follow-up. General Hospital Psychiatry, 2017, 44, 16-21.	2.4	33
7	Consequences of the Convergence of Multiple Alternate Pathways on the Estrogen Receptor in the Treatment of Metastatic Breast Cancer. Clinical Breast Cancer, 2017, 17, 79-90.	2.4	23
8	Postsurgical Depressive Symptoms and Proinflammatory Cytokine Elevations in Women Undergoing Primary Treatment for Breast Cancer. Psychosomatic Medicine, 2016, 78, 26-37.	2.0	55
9	Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians. Breast Cancer Research and Treatment, 2016, 158, 113-126.	2.5	79
10	Ethnic differences in types of social support from multiple sources after breast cancer surgery. Ethnicity and Health, 2016, 21, 411-425.	2.5	12
11	Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials, 2015, 16, 575.	1.6	28
12	Brief cognitive–behavioral and relaxation training interventions for breast cancer: A randomized controlled trial Journal of Consulting and Clinical Psychology, 2015, 83, 677-688.	2.0	78
13	Randomized controlled trial of cognitive behavioral stress management in breast cancer: A brief report of effects on 5-year depressive symptoms Health Psychology, 2015, 34, 176-180.	1.6	44
14	A randomized controlled trial of cognitive-behavioral stress management in breast cancer: survival and recurrence at 11-year follow-up. Breast Cancer Research and Treatment, 2015, 154, 319-328.	2.5	91
15	Comparative Effectiveness Analysis of Monotherapy With Cytotoxic Agents in Triple-negative Metastatic Breast Cancer in a Community Setting. Clinical Therapeutics, 2015, 37, 134-144.	2.5	13
16	Longâ€ŧerm psychological benefits of cognitiveâ€behavioral stress management for women with breast cancer: 11â€year followâ€up of a randomized controlled trial. Cancer, 2015, 121, 1873-1881.	4.1	142
17	Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2â^' Advanced Breast Cancer From a US Payer Perspective. Clinical Breast Cancer, 2015, 15, e263-e276.	2.4	21
18	Improved Clinical Outcomes Associated With Vitamin D Supplementation During Adjuvant Chemotherapy in Patients With HER2+ Nonmetastatic Breast Cancer. Clinical Breast Cancer, 2015, 15, e1-e11.	2.4	69

#	Article	IF	CITATIONS
19	Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy. Medical Oncology, 2014, 31, 163.	2.5	22
20	Participation in Cancer Clinical Trials. Medical Decision Making, 2014, 34, 116-126.	2.4	111
21	Sleep Quality and Fatigue after a Stress Management Intervention for Women with Early-Stage Breast Cancer in Southern Florida. International Journal of Behavioral Medicine, 2014, 21, 971-981.	1.7	56
22	Can mammographic and sonographic imaging features predict the Oncotype DXâ,,¢ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?. Breast Cancer Research and Treatment, 2014, 148, 117-123.	2.5	21
23	Circulating tumor cells in breast cancer. Journal of Carcinogenesis, 2014, 13, 8.	2.5	21
24	Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Research and Treatment, 2014, 147, 433-441.	2.5	17
25	Extending the Clinical Benefit of Endocrine Therapy for Women With Hormone Receptor–Positive Metastatic Breast Cancer: Differentiating Mechanisms of Action. Clinical Breast Cancer, 2014, 14, 75-84.	2.4	25
26	nab-Paclitaxel for the Treatment of Aggressive Metastatic Breast Cancer. Clinical Breast Cancer, 2014, 14, 221-227.	2.4	32
27	Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from two phase II, multicenter, single-arm studies Journal of Clinical Oncology, 2014, 32, 629-629.	1.6	0
28	A comparative effectiveness analysis of single-agent cytotoxics in triple-negative metastatic breast cancer (TN-MBC) patients Journal of Clinical Oncology, 2014, 32, e17648-e17648.	1.6	0
29	Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Research and Treatment, 2013, 138, 21-35.	2.5	123
30	Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2013, 139, 759-767.	2.5	90
31	A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer. Breast Cancer Research and Treatment, 2013, 137, 187-193.	2.5	25
32	Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer. Breast, 2013, 22, 142-149.	2.2	10
33	Nonsteroidal Anti-inflammatory Drug Induced Thrombotic Thrombocytopenic Purpura. Plasmatology, 2013, 6, CMBD.S12843.	0.4	6
34	Molecular Profiling for Breast Cancer: A Comprehensive Review. Biomarkers in Cancer, 2013, 5, BIC.S9455.	3.6	152
35	Macrophages as independent prognostic factors in small T1 breast cancers. Oncology Reports, 2013, 29, 141-148.	2.6	12
36	Biologic Impact and Clinical Implication of mTOR Inhibition in Metastatic Breast Cancer. International Journal of Biological Markers, 2013, 28, 233-241.	1.8	3

#	Article	IF	CITATIONS
37	Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in postmenopausal Early Breast Cancer. Clinical Medicine Insights Women's Health, 2013, 6, CMWH.S8692.	0.6	3
38	Treating Breast Cancer in the 21st Century: Emerging Biological Therapies. Journal of Cancer, 2013, 4, 117-132.	2.5	140
39	Ductal carcinoma <i>in situ</i> : how should we treat it?. Breast Cancer Management, 2013, 2, 245-256.	0.2	0
40	Gene expression profiling in breast cancer. American Journal of Translational Research (discontinued), 2013, 5, 132-8.	0.0	10
41	Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues regarding Dual HER2-Targeted Therapy. Breast Cancer: Basic and Clinical Research, 2012, 6, BCBCR.S9301.	1.1	10
42	Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer. Case Reports in Oncology, 2012, 5, 687-692.	0.7	7
43	Using modern molecular markers to tailor breast cancer treatment: a new era for personalized medicine. Breast Cancer Management, 2012, 1, 105-108.	0.2	2
44	HER2-positive metastatic breast cancer: a double-edged sword. Breast Cancer Management, 2012, 1, 181-184.	0.2	1
45	Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?. Expert Opinion on Therapeutic Targets, 2012, 16, S17-S22.	3.4	9
46	Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Research and Treatment, 2012, 135, 355-366.	2.5	49
47	Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treatment Reviews, 2012, 38, 143-151.	7.7	40
48	Eribulin monotherapy in a patient with heavily pretreated metastatic breast cancer: Case study and review of the literature. Journal of Solid Tumors, 2012, 3, .	0.1	1
49	TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine±Âtrastuzumab. Breast Cancer Research and Treatment, 2012, 132, 781-791.	2.5	194
50	A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Research and Treatment, 2012, 132, 747-751.	2.5	56
51	Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?. Current Oncology Reports, 2012, 14, 1-11.	4.0	77
52	Novel Cytotoxic Agents in the Treatment of Metastatic Breast Cancer. Current Breast Cancer Reports, 2012, 4, 75-82.	1.0	1
53	Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert Review of Clinical Pharmacology, 2011, 4, 329-334.	3.1	65
54	Adjuvant Therapy for Early Breast Cancer. , 2011, , .		0

#	Article	IF	CITATIONS
55	Successful Use of Biweekly Gemcitabine Plus Nab-Paclitaxel in Two Male Patients With Stage IV Breast Cancer: Case Reports and Review of the Literature. American Journal of Therapeutics, 2011, 18, e12-e18.	0.9	3
56	Surviving Metastatic Breast Cancer for 18 Years: A Case Report and Review of the Literature. Breast Journal, 2011, 17, 521-524.	1.0	3
57	Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Breast Cancer Research and Treatment, 2011, 125, 431-439.	2.5	16
58	Stress Management Skills and Reductions in Serum Cortisol Across the Year After Surgery for Non-Metastatic Breast Cancer. Cognitive Therapy and Research, 2011, 35, 595-600.	1.9	28
59	Optimizing Chemotherapy-Free Survival for the ER/HER2-Positive Metastatic Breast Cancer Patient. Clinical Cancer Research, 2011, 17, 5559-5561.	7.0	33
60	Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer. American Journal of Health-System Pharmacy, 2011, 68, 1699-1706.	1.0	10
61	Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women. Breast Cancer: Basic and Clinical Research, 2011, 5, BCBCR.S6234.	1.1	13
62	Chemotherapy regimens in metastatic breast cancer. Clinical Advances in Hematology and Oncology, 2011, 9, 47-8.	0.3	0
63	Exemestane as First-Line Therapy in Postmenopausal Women With Recurrent or Metastatic Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 314-319.	1.3	15
64	Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment, 2010, 123, 427-435.	2.5	76
65	Foreword. Expert Opinion on Investigational Drugs, 2010, 19, S1-S2.	4.1	0
66	Rational combinations in metastatic breast cancer: bevacizumab with chemotherapy. Community Oncology, 2010, 7, 253-262.	0.2	0
67	Improving outcomes in early-stage breast cancer. Oncology, 2010, 24, 1-15.	0.5	19
68	A woman's heart. Cancer, 2009, 115, 1813-1826.	4.1	81
69	NOAH Study: Is It Really Setting the New Standard for Preoperative Systemic Therapy in HER2-Positive Early Breast Cancer?. Breast Diseases, 2009, 20, 138-139.	0.0	0
70	Lapatinib Plus Capecitabine Resolved Human Epidermal Growth Factor Receptor 2-Positive Brain Metastases. American Journal of Therapeutics, 2009, 16, 585-590.	0.9	21
71	A Phase II Trial of Split, Low-Dose Docetaxel and Low-Dose Capecitabine: A Tolerable and Efficacious Regimen in the First-Line Treatment of Patients with HER2/neu–Negative Metastatic Breast Cancer. Clinical Breast Cancer, 2008, 8, 162-167.	2.4	11
72	Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16. Journal of Clinical Oncology, 2008, 26, 37-43.	1.6	53

#	Article	IF	CITATIONS
73	Stress Management Intervention Reduces Serum Cortisol and Increases Relaxation During Treatment for Nonmetastatic Breast Cancer. Psychosomatic Medicine, 2008, 70, 1044-1049.	2.0	100
74	XeNA: Capecitabine Plus Docetaxel, With or Without Trastuzumab, as Preoperative Therapy for Early Breast Cancer. International Journal of Medical Sciences, 2008, 5, 341-346.	2.5	15
75	Gemcitabine and taxanes in metastatic breast cancer: a systematic review. Therapeutics and Clinical Risk Management, 2008, 4, 1157-64.	2.0	9
76	Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?. Clinical Advances in Hematology and Oncology, 2008, 6, 666-72.	0.3	6
77	The Prevention and Management of Distant Metastases in Women with Breast Cancer. Cancer Investigation, 2007, 25, 6-13.	1.3	18
78	Paclitaxel albumin-bound particles (abraxaneâ,,¢) in combination with bevacizumab with or without gemcitabine: Early experience at the University of Miami/Braman Family Breast Cancer Institute. Biomedicine and Pharmacotherapy, 2007, 61, 531-533.	5.6	23
79	How stress management improves quality of life after treatment for breast cancer Journal of Consulting and Clinical Psychology, 2006, 74, 1143-1152.	2.0	236
80	The 3rd InterAmerican Breast Cancer Conference Fiesta Americana Grand Coral Beach Hotel, Cancun, Mexico July 27–29, 2006. Breast Cancer Online: BCO, 2006, 9, 1-2.	0.1	0
81	Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity. Head and Neck, 2006, 28, 189-196.	2.0	24
82	Acceleration of Telomere Loss by Chemotherapy Is Greater in Older Patients with Locally Advanced Head and Neck Cancer. Clinical Cancer Research, 2006, 12, 6345-6350.	7.0	48
83	How Stress Management Improves Quality of Life After Treatment for Breast Cancer Journal of Consulting and Clinical Psychology, 2006, 74, 1143-1152.	2.0	158
84	Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of Epirubicin. Oncologist, 2005, 10, 780-791.	3.7	55
85	Comparison of CD34 and Monocyte-Derived Dendritic Cells from Mobilized Peripheral Blood from Cancer Patients. Stem Cells, 2005, 23, 74-81.	3.2	27
86	New advances in the management of metastatic breast cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3 Suppl 1, S12-6.	4.9	1
87	Priming with Dendritic Cells Can Generate Strong Cytotoxic T Cell Responses to Chronic Myelogenous Leukemia Cells In Vitro. Stem Cells and Development, 2004, 13, 211-221.	2.1	2
88	The Expanding Role of Epirubicin in the Treatment of Breast Cancer. Cancer Control, 2002, 9, 16-27.	1.8	15
89	Generation of dendritic cells: role of cytokines and potential clinical applications. Transfusion and Apheresis Science, 2001, 24, 117-124.	1.0	12
90	Generation of Dendritic Cells Ex Vivo: Differences in Steady State Versus Mobilized Blood from Patients with Breast Cancer, with Lymphoma, and from Normal Donors. Journal of Hematotherapy and Stem Cell Research, 2001, 10, 621-630.	1.8	8

#	Article	IF	CITATIONS
91	The worldwide perspective in the adjuvant treatment of primary lymph node positive breast cancer. Breast Cancer, 2001, 8, 321-328.	2.9	5
92	Effects of Cytokines on the Culture and Differentiation of Dendritic Cells In Vitro. Journal of Hematotherapy and Stem Cell Research, 2001, 10, 43-51.	1.8	17
93	Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells. Breast Cancer Research and Treatment, 2000, 59, 231-244.	2.5	38
94	Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial. Journal of Clinical Oncology, 1999, 17, 846-846.	1.6	597
95	Lack of modulation ofMDR1 gene expression by dominant inhibition of cAMP-dependent protein kinase in doxorubicin-resistant mcf-7 breast cancer cells. , 1999, 82, 893-900.		15
96	Bacterial decontamination of blood stem cell apheresis products. Journal of Clinical Apheresis, 1998, 13, 103-107.	1.3	7
97	The Selective Uptake of Benzoporphyrin Derivative Mono-Acid Ring A Results in Differential Cell Kill of Multiple Myeloma Cells in vitro. Photochemistry and Photobiology, 1996, 63, 846-853.	2.5	20
98	Characterization and transfusion of in vitro cultivated hematopoietic progenitor cells. Transfusion Science, 1995, 16, 273-281.	0.6	6
99	Radiosensitivity of human clonogenic myeloma cells and normal bone marrow precursors: Effect of different dose rates and fractionation. International Journal of Radiation Oncology Biology Physics, 1994, 28, 877-882.	0.8	19